Novo Nordisk's experimental obesity drug, amycretin, demonstrated significant weight loss in early-stage clinical trials, raising hopes for a new treatment option for millions battling obesity.
Shares of Novo Nordisk surged on Friday following the announcement of positive early-stage results for its once-weekly amycretin obesity drug. The trial demonstrated that the injectable treatment led to an average weight reduction of 22% in obese and overweight patients over a period of 36 weeks. Amycretin targets the same gut hormone mimicked by Wegovy, known as GLP-1 , as well as a pancreas hormone called amylin, which plays a role in regulating hunger.
Wegovy is Novo Nordisk's leading obesity medication, while Ozempic is its diabetes treatment. Novo Nordisk stated that the most frequently reported adverse effects of amycretin treatment were gastrointestinal, with the vast majority classified as mild to moderate in severity. 'We are highly encouraged by the subcutaneous phase 1b/2a results for amycretin in individuals living with overweight or obesity,' said Martin Lange, Executive Vice President for Development at Novo Nordisk, in a statement. 'The results observed in the trial support the weight-lowering potential of this novel unimolecular GLP-1 and amylin receptor agonist, amycretin, which we have previously observed with the oral formulation.' This breakthrough comes amidst growing global concerns about the obesity epidemic, highlighting the urgent need for effective weight management solutions. Novo Nordisk's amycretin holds significant promise as a potential game-changer in the fight against obesity, offering a convenient and effective treatment option for millions of individuals struggling with excess weight
NOVO NORDISK AMYCRETIN OBESITY DRUG TRIAL GLP-1 AMYLIN WEIGHT LOSS
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk's Higher-Dose Semaglutide Shows Promising Results in Obesity TrialA new study by Novo Nordisk shows that a 7.2 milligram dose of semaglutide leads to significant weight loss in individuals with obesity, exceeding the effects of currently available semaglutide-based medications.
Read more »
European markets rise; Novo Nordisk shares up 2.5%European stocks were higher on Friday, as markets in the region reopened following a closure for the Christmas holiday.
Read more »
Stocks to Watch Before the Bell: SolarEdge, Novo Nordisk, AMD, Carvana, and MoreGet the latest pre-market stock movers, including SolarEdge, Novo Nordisk, Advanced Micro Devices, Carvana, and more.
Read more »
US to Negotiate Prices for Novo Nordisk's Ozempic and WegovyThe US government plans to negotiate lower prices for Novo Nordisk's popular weight loss and diabetes drugs, Ozempic and Wegovy, as part of a broader effort to reduce drug costs for Medicare. This move comes as the company faces other challenges, including disappointing clinical trial results and investigations into potential side effects.
Read more »
Crypto Stocks Soar Amid Trump Executive Order Rumors, While Novo Nordisk and J.B. Hunt Face DownturnsThis article highlights the midday trading performance of various companies, focusing on the surge in crypto-related stocks due to reports of a potential executive order by President-elect Donald Trump, the decline in Novo Nordisk's share price after its drug semaglutide was included in Medicare's price negotiation list, and the drop in J.B. Hunt's stock after missing fourth-quarter earnings expectations. It also covers the gains in Qorvo, MoonLake Immunotherapeutics, Lam Research, Applied Materials, and Life360, along with Intel's significant rise amidst takeover speculation.
Read more »
Medicare to Implement Price Controls on 15 High-Cost Drugs, Including Novo Nordisk's Wegovy and OzempicThe Centers for Medicare & Medicaid Services (CMS) has announced a second list of 15 prescription drugs subject to price controls under Medicare Part D, aiming to reduce costs for seniors. The list includes popular weight-loss and diabetes medications like Wegovy and Ozempic from Novo Nordisk, as well as cancer treatments. While the administration celebrates this as a success, pharmaceutical companies like Novo Nordisk remain critical, arguing that government price setting could negatively impact patient access and stifle future drug development.
Read more »